Tovorafenib (TAK-580, MLN 2480) acts by counteracting the feedback activation of MEK triggered by TAK-733, resulting in more coordinated inhibition of the MAPK pathway [1].
体内研究
Tovorafenib (TAK-580, MLN 2480) suppresses MAPK pathway signaling in preclinical cancer models harboring BRAF mutations and certain RAS mutations at concentrations tolerated in vivo. TAK-580 (MLN 2480) demonstrates heightened efficacy in BRAF mutant melanoma models, and it also exhibits activity as a single agent in select RAS mutant models. Combination therapy involving MLN2480 with TAK-733 impedes the growth of a wider spectrum of RAS mutant tumor models compared to TAK-580 (MLN 2480) alone, including primary human tumor xenograft models of melanoma and CRC [1].
体外研究
Tovorafenib (TAK-580, MLN 2480) acts by counteracting the feedback activation of MEK triggered by TAK-733, resulting in more coordinated inhibition of the MAPK pathway [1].
搜索
